Evidence map›Paper›PMID 25610594›Full record

ArticlePulmonary circulation2014

Vascular stiffening in pulmonary hypertension: cause or consequence? (2013 Grover Conference series).

Wei Tan, Krishna Madhavan, Kendall S Hunter, Daewon Park, Kurt R Stenmark

Open access · bronzeAbstract read
In one paragraph

Article in Pulmonary circulation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Postnatal pulmonary artery development from transcript to tissue.Journal of the Royal Society, Interface · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Deciphering the Tenascin-C Nexus: A Comprehensive Review of Its Involvement in Chronic Respiratory Diseases.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Review
  9. Observational
  10. Article
  11. LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  12. Article
  13. Article
  14. Pulmonary Vascular Dysfunctions in Cystic Fibrosis.Physiology (Bethesda, Md.) · 2024
    Review
  15. Article
  16. Characterization of pulmonary arterial stiffness using cardiac MRI.The international journal of cardiovascular imaging · 2024
    Review
  17. Review
  18. New Drugs and Therapies in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2023
    Review
  19. Clinical Translation of Engineered Pulmonary Vascular Models.Advances in experimental medicine and biology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Wei TanDepartment of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA ; Cardiovascular Pulmonary Research Laboratories, University of Colorado Denver, Aurora, Colorado, USA ; Department of Mechanical Engineering, University of Colorado Boulder, Boulder, Colorado, USA.
Krishna MadhavanDepartment of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA ; Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA.
Kendall S HunterDepartment of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA ; Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA.
Daewon ParkDepartment of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA.
Kurt R StenmarkDepartment of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA ; Cardiovascular Pulmonary Research Laboratories, University of Colorado Denver, Aurora, Colorado, USA.
University of Colorado Denver · USUniversity of Colorado Boulder · US

Funding

VRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1M
Fibroblasts and Mononuclear Fibrogenic Cells Drive Right Ventricular Pulmonary ArR01HL114887 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BULL, TODD M, BUTTRICK, PETER N. · 2012 to 2016
$3.4M
NHLBI NIH HHS P01 HL014985NHLBI NIH HHS R01 HL114887
6 · The paper itself

Abstract

Recent studies have indicated that systemic arterial stiffening is a precursor to hypertension and that hypertension, in turn, can perpetuate arterial stiffening. Pulmonary artery (PA) stiffening is also well documented to occur in pulmonary hypertension (PH), and there is evidence that pulmonary vascular stiffness (PVS) may be a better predictor of outcome than pulmonary vascular resistance (PVR). We have hypothesized that the decreased flow-damping function of elastic PAs in PH likely initiates and/or perpetuates dysfunction of pulmonary microvasculature. Recent studies have shown that large-vessel stiffening increases flow pulsatility in the distal pulmonary vasculature, leading to endothelial dysfunction within a proinflammatory, vasoconstricting, and profibrogenic environment. The intricate role of stiffening-stimulated high pulsatile flow in endothelial cell dysfunction includes stepwise molecular events underlying PA hypertrophy, inflammation, endothelial-mesenchymal transition, and fibrosis. In addition to contributing to microenvironmental alterations of the distal vasculature, disordered proximal-distal PA coupling likely also plays a role in increasing ventricular afterload, ultimately causing right ventricle (RV) dysfunction and death. Current therapeutic treatments do not provide a realistic approach to destiffening arteries and, thus, to potentially abrogating the effects of high pulsatile flow on the distal pulmonary vasculature or the increased work imposed by stiffening on the RV. Scrutinizing the effect of PA stiffening on high pulsatile flow-induced cellular and molecular changes, and vice versa, might lead to important new therapeutic options that abrogate PA remodeling and PH development. With a clear understanding that PA stiffening may contribute to the progression of PH to an irreversible state by contributing to chronic microvascular damage in lungs, future studies should be aimed first at defining the underlying mechanisms leading to PA stiffening and then at improved treatment approaches based on these findings.

Indexed as

arterial stiffeningendothelial cellinflammationpulmonary hypertensionright ventriclesmooth muscle celltreatmentwave reflection

Identifiers

PMID25610594
PMCPMC4278618
OpenAlexW2014295218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.